Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab and FESS in CRSwNP
NCT05598814Phase 4Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms). Primary endpoint: Sino-Nasal Outcome Test 22 at 6 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05598814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598814.